Douglas Van Nostrand
Research Subjects
Douglas Van Nostrand has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Leonard Wartofsky
Division of Endocrinology, MedStar Health Washington Hospital Center, Washington, DC
18 shared publicationsFrank Atkins
Division of Nuclear Medicine, MedStar Health Washington Hospital Center, Washington, DC
10 shared publicationsKenneth D. Burman
Division of Endocrinology, MedStar Health Washington Hospital Center, Washington, DC
10 shared publicationsShari Moreau
Division of Nuclear Medicine, MedStar Washington Hospital Center, Washington, District of Columbia
8 shared publicationsCarlos Garcia
Division of Nuclear Medicine, MedStar Washington Hospital Center, Washington, USA
6 shared publicationsDi Wu
Division, Nuclear Medicine Research, MedStar Health Research Institute, Hyattsville, USA
6 shared publications
Latest Publications
- 4 February 2022
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 36 (3) , 213-223
I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response
Purpose The objective of this study is to evaluate the lesion absorbed dose (AD), biological effective dose (BED), and equivalent uniform dose (EUD) to clinical–response relationship in lesional dosimetry for 131I therapy. Methods Nineteen lesions in four patients with metastatic differentiated thyroid cancer (DTC) were evaluated. The patients underwent PET/CT imaging at 2 h, 24 h, 48 h, 72 h, and 96 h post administration of ~ 33–65 MBq (0.89–1.76 mCi) of 124I before undergoing 131I therapy. The 124I PET/CT images were used to perform dosimetry calculations for 131I therapy. Lesion dose–rate values were calculated using the time–activity data and integrated over the measured time points to obtain AD and BED. The Geant4 toolkit was used to run Monte Carlo on spheres the same size as the lesions to estimate EUD. The lesion AD, BED, and EUD values were correlated with response data (i.e. change in lesion size pre- and post-therapy): complete response (CR, i.e. disappearance of the lesion), partial response (PR, i.e. any decrease in lesion length), stable disease (SD, i.e., no change in length), and progressive disease (PD, i.e., any increase in length). Results The lesion responses were CR and PR (58%, 11/19 lesions), SD (21%, 4/19), and PD (21%, 4/19). For CR and PR lesions, the ADs, BEDs and EUDs were > 75 Gy for 82% (9/11) and < 75 Gy for 18% (2/11). The ADs and BEDs were < 75 Gy for SD and PD lesions. Conclusion By performing retrospective dosimetry calculations for 131I therapy based on 124I PET/CT imaging, we evaluated the correlation of three dosimetric quantities to lesional response. When lesion AD, BED, and EUD values were > 75 Gy, 47% (9/19) of the lesions had a CR or PR. The AD, BED, and EUD values for SD and PD lesions were < 75 Gy. The data presented herein suggest that the greater the lesion AD, BED, and/or EUD, the higher the probability of a therapeutic response to 131I therapy.
- 4 February 2022
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 36 (3) , 213-223
I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response
Purpose The objective of this study is to evaluate the lesion absorbed dose (AD), biological effective dose (BED), and equivalent uniform dose (EUD) to clinical–response relationship in lesional dosimetry for 131I therapy. Methods Nineteen lesions in four patients with metastatic differentiated thyroid cancer (DTC) were evaluated. The patients underwent PET/CT imaging at 2 h, 24 h, 48 h, 72 h, and 96 h post administration of ~ 33–65 MBq (0.89–1.76 mCi) of 124I before undergoing 131I therapy. The 124I PET/CT images were used to perform dosimetry calculations for 131I therapy. Lesion dose–rate values were calculated using the time–activity data and integrated over the measured time points to obtain AD and BED. The Geant4 toolkit was used to run Monte Carlo on spheres the same size as the lesions to estimate EUD. The lesion AD, BED, and EUD values were correlated with response data (i.e. change in lesion size pre- and post-therapy): complete response (CR, i.e. disappearance of the lesion), partial response (PR, i.e. any decrease in lesion length), stable disease (SD, i.e., no change in length), and progressive disease (PD, i.e., any increase in length). Results The lesion responses were CR and PR (58%, 11/19 lesions), SD (21%, 4/19), and PD (21%, 4/19). For CR and PR lesions, the ADs, BEDs and EUDs were > 75 Gy for 82% (9/11) and < 75 Gy for 18% (2/11). The ADs and BEDs were < 75 Gy for SD and PD lesions. Conclusion By performing retrospective dosimetry calculations for 131I therapy based on 124I PET/CT imaging, we evaluated the correlation of three dosimetric quantities to lesional response. When lesion AD, BED, and EUD values were > 75 Gy, 47% (9/19) of the lesions had a CR or PR. The AD, BED, and EUD values for SD and PD lesions were < 75 Gy. The data presented herein suggest that the greater the lesion AD, BED, and/or EUD, the higher the probability of a therapeutic response to 131I therapy.
- 21 January 2021
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 46 (4) , 283-288
Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid Cancer
Background: The objective of this study was to determine the optimal time for 124I PET/CT imaging to maximize the detection of locoregional and/or distant metastases of differentiated thyroid cancer. Methods: Differentiated thyroid cancer patients suspected of having metastatic disease were prepared with low-iodine diet and appropriate thyroid-stimulating hormone stimulation. 124I PET and low-dose localization CT were performed over 4 days after oral administration of 31.5 or 62.9 MBq (0.85 or 1.7 mCi) of 124I. Each scan was independently reviewed by 2 nuclear medicine physicians. All foci of activity were categorized, and the visual intensity of uptake was scored by a semiquantitative 3-point grading system (1: mild uptake, 2: moderate uptake, 3: intense uptake). Lesion volumes were determined on the CT image or on the PET images. Background (bkg) was also measured for each lesion and on each individual PET image. For each lesion, the mean activity concentration rate per unit administered activity (ACRmean/AA) and lesion-to-bkg ratios were compared across the 5 different time points. The semiquantitative grade and the quantitative measurements were compared. Results: A total of 45 124I PET/CT scans were reviewed for 9 patients. In the visual assessment, a total of 31 foci suggestive for or highly suggestive of metastasis were identified on 124I PET/CT. Of these, 6 were seen on the 2-h, 18 on the 24-h, 27 on the 48-h, 24 on the 72-h, and 20 on the 96-h scan. There was a significant difference between the 24- and 48-h scans in the total number of foci (ie, locoregional and distant metastasis) (P < 0.05) and in the number of distant metastases (P < 0.05). The 24-, 48-, and 72-h scans identified the same number of locoregional foci. The 48-h scan visualized more of the distant metastases than any other time point. 124I PET/CT with dual-time-point imaging was superior to single-time-point imaging (97% vs 87%). In the quantitative analysis, the median ACRmean/AA was highest at 24 and 48 h, and the median lesion-to-bkg ratio was variable for different lesion locations. For lung metastases, the highest median lesion-to-bkg ratio was at 72 and 96 h. Conclusions: 124I PET/CT with dual-time-point imaging was superior to any single-time-point imaging (P < 0.10). Based on the visual assessment, dual time points at 48 + 72 h or 48 + 96 h yielded the highest lesion detection rate, whereas for single-time-point imaging, the 48-h images had the highest lesion detection rate. If the 48-h scan is completely negative or has negative 124I uptake in the region of interest, then a 72- or 96-h scan may be valuable. If lung metastases are suspected, then one should consider additional imaging at 72 or 96 h.
- 21 January 2021
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 46 (4) , 283-288
Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid Cancer
Background: The objective of this study was to determine the optimal time for 124I PET/CT imaging to maximize the detection of locoregional and/or distant metastases of differentiated thyroid cancer. Methods: Differentiated thyroid cancer patients suspected of having metastatic disease were prepared with low-iodine diet and appropriate thyroid-stimulating hormone stimulation. 124I PET and low-dose localization CT were performed over 4 days after oral administration of 31.5 or 62.9 MBq (0.85 or 1.7 mCi) of 124I. Each scan was independently reviewed by 2 nuclear medicine physicians. All foci of activity were categorized, and the visual intensity of uptake was scored by a semiquantitative 3-point grading system (1: mild uptake, 2: moderate uptake, 3: intense uptake). Lesion volumes were determined on the CT image or on the PET images. Background (bkg) was also measured for each lesion and on each individual PET image. For each lesion, the mean activity concentration rate per unit administered activity (ACRmean/AA) and lesion-to-bkg ratios were compared across the 5 different time points. The semiquantitative grade and the quantitative measurements were compared. Results: A total of 45 124I PET/CT scans were reviewed for 9 patients. In the visual assessment, a total of 31 foci suggestive for or highly suggestive of metastasis were identified on 124I PET/CT. Of these, 6 were seen on the 2-h, 18 on the 24-h, 27 on the 48-h, 24 on the 72-h, and 20 on the 96-h scan. There was a significant difference between the 24- and 48-h scans in the total number of foci (ie, locoregional and distant metastasis) (P < 0.05) and in the number of distant metastases (P < 0.05). The 24-, 48-, and 72-h scans identified the same number of locoregional foci. The 48-h scan visualized more of the distant metastases than any other time point. 124I PET/CT with dual-time-point imaging was superior to single-time-point imaging (97% vs 87%). In the quantitative analysis, the median ACRmean/AA was highest at 24 and 48 h, and the median lesion-to-bkg ratio was variable for different lesion locations. For lung metastases, the highest median lesion-to-bkg ratio was at 72 and 96 h. Conclusions: 124I PET/CT with dual-time-point imaging was superior to any single-time-point imaging (P < 0.10). Based on the visual assessment, dual time points at 48 + 72 h or 48 + 96 h yielded the highest lesion detection rate, whereas for single-time-point imaging, the 48-h images had the highest lesion detection rate. If the 48-h scan is completely negative or has negative 124I uptake in the region of interest, then a 72- or 96-h scan may be valuable. If lung metastases are suspected, then one should consider additional imaging at 72 or 96 h.
- 14 December 2020
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 42 (3) , 292-299
The spectrum of 124I uptake in the lacrimal gland and nasolacrimal sac/duct on PET/CT imaging
Introduction: This study characterizes the spectrum of physiologic 124I uptake of the lacrimal system in patients with a history of differentiated thyroid cancer (DTC) who underwent multi-timepoint 124I PET/CT imaging. Methods: 124I PET/CT in 31 DTC patients was performed at 2, 24, 48, 72, and 96 h after oral administration of 31.5 or 62.9 MBq (0.85 or 1.7 mCi) of 124I after either recombinant human thyroid-stimulating hormone injections or thyroid hormone withdrawal. All but two patients had a history of prior 131I therapy. Patterns of 124I uptake in the lacrimal glands and nasolacrimal sac/ducts (NLD) were assessed. Results: A total of 173 individual 124I PET/CT scans (forming 35 sets of scans) were reviewed for 31 patients. Lacrimal glands were visualized bilaterally in only 4 patients. The focal mild uptake (grade 2), best seen on the 2-h images, was crescent-shaped and located in the lateral upper quadrant of the orbit. In contrast, the NLDs were identified in all patients (bilateral in 29 of 31 patients) with high focal uptake (grade 4) peaking on the 2- and 24-h timepoints; however, the overall pattern of uptake was variable. Of the 29 patients with prior 131I therapy, three patients had a relatively fixed and unchanging pattern of uptake on at least one side of the NLDs. Conclusions: In patients with DTC, 124I activity in the NLDs is more frequently visualized, more intense, more prolonged, and more variable than in the lacrimal glands. The lack of clearance may suggest possible obstruction or stasis of an NLD.
- 14 December 2020
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 42 (3) , 292-299
The spectrum of 124I uptake in the lacrimal gland and nasolacrimal sac/duct on PET/CT imaging
Introduction: This study characterizes the spectrum of physiologic 124I uptake of the lacrimal system in patients with a history of differentiated thyroid cancer (DTC) who underwent multi-timepoint 124I PET/CT imaging. Methods: 124I PET/CT in 31 DTC patients was performed at 2, 24, 48, 72, and 96 h after oral administration of 31.5 or 62.9 MBq (0.85 or 1.7 mCi) of 124I after either recombinant human thyroid-stimulating hormone injections or thyroid hormone withdrawal. All but two patients had a history of prior 131I therapy. Patterns of 124I uptake in the lacrimal glands and nasolacrimal sac/ducts (NLD) were assessed. Results: A total of 173 individual 124I PET/CT scans (forming 35 sets of scans) were reviewed for 31 patients. Lacrimal glands were visualized bilaterally in only 4 patients. The focal mild uptake (grade 2), best seen on the 2-h images, was crescent-shaped and located in the lateral upper quadrant of the orbit. In contrast, the NLDs were identified in all patients (bilateral in 29 of 31 patients) with high focal uptake (grade 4) peaking on the 2- and 24-h timepoints; however, the overall pattern of uptake was variable. Of the 29 patients with prior 131I therapy, three patients had a relatively fixed and unchanging pattern of uptake on at least one side of the NLDs. Conclusions: In patients with DTC, 124I activity in the NLDs is more frequently visualized, more intense, more prolonged, and more variable than in the lacrimal glands. The lack of clearance may suggest possible obstruction or stasis of an NLD.
- Open Access
- 1 July 2020
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 19 (03) , 266-270
30 mCi exploratory scan for two-step dosimetric 131I therapy in differentiated thyroid cancer patients: A novel approach and case report
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society
- 1 July 2020
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 19 (03) , 266-270
Open Access30 mCi exploratory scan for two-step dosimetric 131I therapy in differentiated thyroid cancer patients: A novel approach and case report
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society
- 26 August 2019
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 61 (3) , 397-404
Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer
The objective of this nationwide survey was to evaluate whether there has been a change in the practice regarding hospital release of differentiated thyroid cancer patients treated with 131I since the publication of Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 addressing patient release. Methods: A survey was emailed to ~25,000 members of ThyCa: Thyroid Cancer Survivors’ Association, Inc. and was available online from March-August 2018. Responses were included from adult patients regarding their most recent 131I therapy received between 2011-2018 (post2011). Responses to this survey were compared to those of a similar previous survey for 131I therapies received between 1997-2009 (pre2009). Results: Of the 2,136 responses, 1,111 met the inclusion criteria. A similar percentage (~98%) of patients were given oral and/or written radiation safety instructions (RSI) post2011 and pre2009 with a shift away from nuclear medicine physicians providing instructions post2011 (43%) than pre2009 (54%; pP = 0.28). Of the 27 outpatients released within 30 minutes to non-private residences, two patients received 5.55-11.1 GBq (150-299 mCi) of 131I. Conclusion: This survey suggests that since publication of the Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 regarding patient release after radioiodine therapy, there has been improvements in some radiation safety practices on release of outpatients, and in patient compliance on travel and lodging.
- 26 August 2019
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 61 (3) , 397-404
Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer
The objective of this nationwide survey was to evaluate whether there has been a change in the practice regarding hospital release of differentiated thyroid cancer patients treated with 131I since the publication of Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 addressing patient release. Methods: A survey was emailed to ~25,000 members of ThyCa: Thyroid Cancer Survivors’ Association, Inc. and was available online from March-August 2018. Responses were included from adult patients regarding their most recent 131I therapy received between 2011-2018 (post2011). Responses to this survey were compared to those of a similar previous survey for 131I therapies received between 1997-2009 (pre2009). Results: Of the 2,136 responses, 1,111 met the inclusion criteria. A similar percentage (~98%) of patients were given oral and/or written radiation safety instructions (RSI) post2011 and pre2009 with a shift away from nuclear medicine physicians providing instructions post2011 (43%) than pre2009 (54%; pP = 0.28). Of the 27 outpatients released within 30 minutes to non-private residences, two patients received 5.55-11.1 GBq (150-299 mCi) of 131I. Conclusion: This survey suggests that since publication of the Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 regarding patient release after radioiodine therapy, there has been improvements in some radiation safety practices on release of outpatients, and in patient compliance on travel and lodging.
- 25 October 2018
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 60 (5) , 638-643
Detection at Public Facilities of 131I in Patients Treated for Differentiated Thyroid Cancer: Frequency, Sites, Management by Security Agents, and Physician Documentation Recommended for Patients
Rationale: Patients treated with 131I may be identified at security checkpoints at various public facilities. The objective of this survey was to determine the frequency of detection, spectrum of public facilities, the various management of these patients by security agents, and the spectrum of physician documentation for the patient regarding his/her 131I therapy. Methods: Data were tabulated from a ThyCa: Thyroid Cancer Survivors’ Association, Inc. (ThyCa) survey emailed to ~15,000 associates and available online from Dec 2013 to Dec 2014. Responses were tabulated from respondents who reported that they were >18 yo, had at least one therapy of 131I for differentiated thyroid cancer, and were responding regarding their last 131I therapy. Results: Of 621 respondents, 595 reported an attempt to pass through a public facility security checkpoint. Of these 595 pts, 9.6%(57) were identified as being radioactive, and of 43 respondents, the facility was an airport in 35%(15), border crossing in 33%(14), government building in 19%(8), shopping mall in 7%(3), train station in 5%(2), and steel recycling plant in 2%(1). Of 47 respondents, the security agent’s management of the patient included questioning 38%(81), allowing to proceed without a change in travel plans 57%(27), requesting documentation of the therapy 55%(26), rescanning 55%(26), calling a member of the treating team for validation 17%(8), “strip” searching 4%(2), detaining such that a change in travel plans was required 6%(3), and/or prohibiting continued travel for 4%(2). Of 47 respondents, they were detained from Conclusion: Detection of radioactivity in public facilities after 131 I therapy occurred in 9.6% of patient-respondents in a variety of security checkpoints. Travel inconvenience is not infrequent and may require altering travel plans. Physicians should take steps to assure that patients not only have appropriate documentation of their 131I therapy with them but also have instructions regarding how the security agent may verify the patients’ 131I therapy.
- 25 October 2018
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 60 (5) , 638-643
Detection at Public Facilities of 131I in Patients Treated for Differentiated Thyroid Cancer: Frequency, Sites, Management by Security Agents, and Physician Documentation Recommended for Patients
Rationale: Patients treated with 131I may be identified at security checkpoints at various public facilities. The objective of this survey was to determine the frequency of detection, spectrum of public facilities, the various management of these patients by security agents, and the spectrum of physician documentation for the patient regarding his/her 131I therapy. Methods: Data were tabulated from a ThyCa: Thyroid Cancer Survivors’ Association, Inc. (ThyCa) survey emailed to ~15,000 associates and available online from Dec 2013 to Dec 2014. Responses were tabulated from respondents who reported that they were >18 yo, had at least one therapy of 131I for differentiated thyroid cancer, and were responding regarding their last 131I therapy. Results: Of 621 respondents, 595 reported an attempt to pass through a public facility security checkpoint. Of these 595 pts, 9.6%(57) were identified as being radioactive, and of 43 respondents, the facility was an airport in 35%(15), border crossing in 33%(14), government building in 19%(8), shopping mall in 7%(3), train station in 5%(2), and steel recycling plant in 2%(1). Of 47 respondents, the security agent’s management of the patient included questioning 38%(81), allowing to proceed without a change in travel plans 57%(27), requesting documentation of the therapy 55%(26), rescanning 55%(26), calling a member of the treating team for validation 17%(8), “strip” searching 4%(2), detaining such that a change in travel plans was required 6%(3), and/or prohibiting continued travel for 4%(2). Of 47 respondents, they were detained from Conclusion: Detection of radioactivity in public facilities after 131 I therapy occurred in 9.6% of patient-respondents in a variety of security checkpoints. Travel inconvenience is not infrequent and may require altering travel plans. Physicians should take steps to assure that patients not only have appropriate documentation of their 131I therapy with them but also have instructions regarding how the security agent may verify the patients’ 131I therapy.
- 31 August 2018
- Published by Wiley in Oral Diseases
- Vol. 25 (1) , 158-163
Poor patient compliance with instructions for continuous sialogogues after 131I therapy
Objectives: To analyze the role of patient compliance as a factor in evaluating the effectiveness of continuous sialogogues to prevent salivary side effects from 131I therapy in differentiated thyroid cancer patients.Methods: Differentiated thyroid cancer patients who were clinically scheduled for an 131I therapy at MedStar Washington Hospital Center between 2012 and 2013 were given instructions for continuous sialogogues per standard clinical protocol. The prospective survey was given at multiple time points.Results: Ninety‐nine patients consented to participate of whom 94 participants had complete data. The mean prescribed 131I activity was 121 ± 50 mCi (4.5 ± 1.9 GBq), range 27.5–288 mCi (1.0–10.7 GBq ). Overall, only 10% (9/94) of patients were compliant with continuous sialogogues. Even though all patients took sialogogues on the first day of post‐therapy, 17% of participants did not continuously take sialogogues during the first day, 60% during the first night, and 72% on the second day despite rigorous instructions to continue for two days.Conclusion: Despite repetitive instructions to use sialogogues continuously, most patients (90%) were not compliant. In future studies, strict monitoring and evaluation of patient compliance will be crucial when assessing the effect of continuous versus intermittent or delayed initiation of sialogogues.
- 31 August 2018
- Published by Wiley in Oral Diseases
- Vol. 25 (1) , 158-163
Poor patient compliance with instructions for continuous sialogogues after 131I therapy
Objectives: To analyze the role of patient compliance as a factor in evaluating the effectiveness of continuous sialogogues to prevent salivary side effects from 131I therapy in differentiated thyroid cancer patients.Methods: Differentiated thyroid cancer patients who were clinically scheduled for an 131I therapy at MedStar Washington Hospital Center between 2012 and 2013 were given instructions for continuous sialogogues per standard clinical protocol. The prospective survey was given at multiple time points.Results: Ninety‐nine patients consented to participate of whom 94 participants had complete data. The mean prescribed 131I activity was 121 ± 50 mCi (4.5 ± 1.9 GBq), range 27.5–288 mCi (1.0–10.7 GBq ). Overall, only 10% (9/94) of patients were compliant with continuous sialogogues. Even though all patients took sialogogues on the first day of post‐therapy, 17% of participants did not continuously take sialogogues during the first day, 60% during the first night, and 72% on the second day despite rigorous instructions to continue for two days.Conclusion: Despite repetitive instructions to use sialogogues continuously, most patients (90%) were not compliant. In future studies, strict monitoring and evaluation of patient compliance will be crucial when assessing the effect of continuous versus intermittent or delayed initiation of sialogogues.
- 24 May 2018
- Published by Springer Nature in Endocrine
- Vol. 62 (1) , 57-63
Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management
The detection of recurrent disease in differentiated thyroid cancer (DTC) patients with elevated or rising serum thyroglobulin (Tg) levels and multiple negative conventional imaging studies can be challenging, especially when 18F-FDG PET/CT scan is also negative. We report a patient and review the literature on the diagnostic use of 99mTc-sestamibi scans to identify the source of elevated or rising Tg in patients with negative conventional imaging including negative 18F-FDG PET/CT scans.
- 24 May 2018
- Published by Springer Nature in Endocrine
- Vol. 62 (1) , 57-63
Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management
The detection of recurrent disease in differentiated thyroid cancer (DTC) patients with elevated or rising serum thyroglobulin (Tg) levels and multiple negative conventional imaging studies can be challenging, especially when 18F-FDG PET/CT scan is also negative. We report a patient and review the literature on the diagnostic use of 99mTc-sestamibi scans to identify the source of elevated or rising Tg in patients with negative conventional imaging including negative 18F-FDG PET/CT scans.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Rapid washout in primary, secondary, and tertiary hyperparathyroidism and utility of dual radiopharmaceutical acquisition with 99 Tc-sestamibi-123I for localization of parathyroid adenomas
99mTc-Sestamibi (SeS) is a standard tool for localization of adenomas/hyperplasia (PA) in hyperparathyroidism (HPTH), designed on the difference between thyroid and parathyroid tissue radiotracer washout on early and late scintigraphy phases. However, PA have been reported to washout as fast as normal thyroid tissue (‘rapid washout’, RW), which may lead to diagnostic failure. The aim of the study was to determine a correlation of RW of SeS from parathyroid glands and types of hyperparathyroidism (HPTH). The utility of dual isotope radiopharmaceutical acquisition with 123I/SeS subtraction imaging (SS) for detection of PA with RW was also investigated. Methods: An IRB approved retrospective review of cases with HPTH referred to nuclear medicine and had subsequent parathyroid surgery was performed. Pre-, post-surgical and biochemical workup of HPTH, surgical pathology reports were analyzed. Correlative imaging with 123I/SeS subtraction imaging was performed on selective patients. Group comparison was performed using paired t-test, ANOVA, and Brown–Forsythe tests. Results: 135 HPTH patients after parathyroidectomy with available dual phase SeS, pathology report, pre- and post-surgical biochemical HPTH workup were analyzed. Ninety-six (71%) patients had primary (p-HPTH), 29 (21%) had secondary (s-HPTH) and 10 (7%) had tertiary (t-HPTH) HPTH. 87/103 (84%) in p-HPTH, 53/94 (56%) in s-HPTH, and 16/23 (69%) in t-HPTH glands were positive on late SeS. RW was identified in 27% (28/103) p-HPTH, 15% (14/94) s-HPTH, 4% (1/23) t-HPTH (PP=0.0036). Median PTH levels for p-HPTH, s-HPTH, and t-HPTH were 142 (IQR:110–240.3), 955 (IQR:1865–2448), 1394 (IQR: 949–2613) pg/ml respectively (PP=0.024) but not with late SeS phase positivity (P=0.26). There was no significant difference in preoperative levels of calcium on retention of SeS radiotracer on early and late phases (P=0.545). Correlative imaging with dual isotope was performed in 17 patients and 123I uptake was positive in 88% of PA with RW. Conclusion: Higher rates of RW were seen in p-HPTH followed by s-HPTH and t-HPTH and was dependent on PA size but neither on PTH nor calcium levels. Pre-operative PTH levels and size of the gland were major determinants of 99mTc-sestamibi positivity on early SeS phase whereas size is an independent predictor of late SeS phase positivity. SS scintigraphy might be a useful tool in suspected cases of RA.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Rapid washout in primary, secondary, and tertiary hyperparathyroidism and utility of dual radiopharmaceutical acquisition with 99 Tc-sestamibi-123I for localization of parathyroid adenomas
99mTc-Sestamibi (SeS) is a standard tool for localization of adenomas/hyperplasia (PA) in hyperparathyroidism (HPTH), designed on the difference between thyroid and parathyroid tissue radiotracer washout on early and late scintigraphy phases. However, PA have been reported to washout as fast as normal thyroid tissue (‘rapid washout’, RW), which may lead to diagnostic failure. The aim of the study was to determine a correlation of RW of SeS from parathyroid glands and types of hyperparathyroidism (HPTH). The utility of dual isotope radiopharmaceutical acquisition with 123I/SeS subtraction imaging (SS) for detection of PA with RW was also investigated. Methods: An IRB approved retrospective review of cases with HPTH referred to nuclear medicine and had subsequent parathyroid surgery was performed. Pre-, post-surgical and biochemical workup of HPTH, surgical pathology reports were analyzed. Correlative imaging with 123I/SeS subtraction imaging was performed on selective patients. Group comparison was performed using paired t-test, ANOVA, and Brown–Forsythe tests. Results: 135 HPTH patients after parathyroidectomy with available dual phase SeS, pathology report, pre- and post-surgical biochemical HPTH workup were analyzed. Ninety-six (71%) patients had primary (p-HPTH), 29 (21%) had secondary (s-HPTH) and 10 (7%) had tertiary (t-HPTH) HPTH. 87/103 (84%) in p-HPTH, 53/94 (56%) in s-HPTH, and 16/23 (69%) in t-HPTH glands were positive on late SeS. RW was identified in 27% (28/103) p-HPTH, 15% (14/94) s-HPTH, 4% (1/23) t-HPTH (PP=0.0036). Median PTH levels for p-HPTH, s-HPTH, and t-HPTH were 142 (IQR:110–240.3), 955 (IQR:1865–2448), 1394 (IQR: 949–2613) pg/ml respectively (PP=0.024) but not with late SeS phase positivity (P=0.26). There was no significant difference in preoperative levels of calcium on retention of SeS radiotracer on early and late phases (P=0.545). Correlative imaging with dual isotope was performed in 17 patients and 123I uptake was positive in 88% of PA with RW. Conclusion: Higher rates of RW were seen in p-HPTH followed by s-HPTH and t-HPTH and was dependent on PA size but neither on PTH nor calcium levels. Pre-operative PTH levels and size of the gland were major determinants of 99mTc-sestamibi positivity on early SeS phase whereas size is an independent predictor of late SeS phase positivity. SS scintigraphy might be a useful tool in suspected cases of RA.
- 1 May 2018
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 125, 111-120
Radioiodine refractory differentiated thyroid cancer
- 1 May 2018
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 125, 111-120
Radioiodine refractory differentiated thyroid cancer